Founded in 2016, Opticyte was spun out of the University of Washington. Currently the medical device startup has secured more than $4.0M in non-dilutive funding from the National Institutes of Health through three SBIR/STTR grants. Opticyte employs engineering, regulatory, and communications teams with deep experience in bringing medical devices to market.
CEO and Co-founder Lori Arakaki’s Vision for Opticyte
We’re solving a big problem in medicine at Opticyte and because of our work, I have no doubt lives will be saved. I’ve dedicated my career to researching, understanding, and building a new technology needed to reveal a critical, missing — and life-saving — insight for clinicians. Opticyte’s Cell O₂ Monitor holds the promise to reduce organ failure and death associated with sepsis. It’s a worthwhile endeavor, given that millions of people suffer the effects of organ failure each year.
The mystery lies in uncovering oxygen levels inside the human body. Current technologies, such as pulse oximeters...
Our Executive Team
Lori Arakaki, PhD
CEO & Co-Founder
Lori Arakaki, PhD is a founder of Opticyte, and her vision and leadership as CEO steadily drive the company towards demonstration of clinical benefit. As CEO, Lori has secured angel and venture capital funding in addition to significant NIH small business grant funding. Lori has over 20 years of experience pioneering new optical spectroscopy and multivariate analysis technology to measure oxygen saturation that will revolutionize the standard of care for critically ill patients and provide breakthrough tools that reduce deaths caused by organ failure. Lori earned her PhD in bioengineering from the University of Washington.
Opticyte board chair and executive advisor Robert Barry is an accomplished medical device entrepreneur/executive with more than 30 years of experience leading companies from inception through commercialization and acquisition. Robert has founded and led four medical device companies to date.
Ken Schenkman, MD, PhD
Chief Medical Officer and Co-Founder
Co-Founder and Opticyte Chief Medical Officer Kenneth Schenkman, MD, PhD, is a critical care physician with extensive and ongoing research experience in optical spectroscopy technologies. His University of Washington lab has secured funding from the National Institutes of Health, American Heart Association and several foundations.
We are always interested in individuals with unique experiences and skills who share our passion to transform the standard of care for organ failure. If you have an interest in our growing company, we would love to hear from you.